Find patient medical information for Auryxia oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

2024年2月18日 · What is Auryxia? Auryxia is used to control phosphorus levels in adults with chronic kidney disease who are on dialysis. Auryxia is also used to treat iron deficiency anemia in adults with chronic kidney disease who are not on dialysis. Auryxia may also be used for purposes not listed in this medication guide.

AURYXIA is a prescription medicine that can lower the amount of phosphate in the blood for adults with chronic kidney disease (CKD) who ARE on dialysis. For adults who have iron deficiency anemia, as well as CKD, and are NOT on dialysis, AURYXIA is a medicine that can increase hemoglobin levels and increase iron levels in the body.

2024年2月5日 · Auryxia (ferric citrate) is a phosphate binder used for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. What Are Side Effects of Auryxia? Common side effects of Auryxia include: dark stools (related to the iron content). Seek medical care or call 911 at once if you have the following serious side effects:

2025年1月7日 · Auryxia (ferric citrate) comes as a 210 mg tablet and is taken by mouth three times per day with meals. It's not available as a generic. Common side effects include dark stools, diarrhea, and constipation.

2024年12月4日 · Detailed dosage guidelines and administration information for Auryxia (ferric citrate). Includes dose adjustments, warnings and precautions.

2025年3月5日 · Learn about the side effects of Auryxia (ferric citrate), from common to rare, for consumers and healthcare professionals.

2024年12月4日 · Tablets: Auryxia 210 mg ferric iron, equivalent to 1 g ferric citrate, film-coated, peach-colored, and oval-shaped tablet debossed with “KX52.” Auryxia is contraindicated in patients with iron overload syndromes (e.g., hemochromatosis) [see Warnings and …

AURYXIA (ah-RICKS-ee-ah) can help you achieve your phosphorus goals. AURYXIA is an iron-based phosphate binder tablet that doesn’t require chewing. In a clinical study, AURYXIA helped people lower their phosphorus levels toward the normal range. This reduction was maintained for over a year of treatment (56 weeks).

Indicated for treatment of iron deficiency anemia in adults with CKD not on dialysis (CKD-NDD) Initial: 210 mg (1 tablet) PO TID with meals. Titrate as needed to achieve and maintain hemoglobin...